Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 9 | 1 |
| List of Figures | 9 | 1 |
| Eisai Co., Ltd. Snapshot | 10 | 1 |
| Eisai Co., Ltd. Overview | 10 | 1 |
| Key Information | 10 | 1 |
| Key Facts | 10 | 1 |
| Eisai Co., Ltd. Research and Development Overview | 11 | 6 |
| Key Therapeutic Areas | 11 | 6 |
| Eisai Co., Ltd. Pipeline Review | 17 | 7 |
| Pipeline Products by Stage of Development | 17 | 1 |
| Pipeline Products Monotherapy | 18 | 1 |
| Pipeline Products Combination Treatment Modalities | 19 | 1 |
| Pipeline Products Partnered Products | 20 | 1 |
| Partnered Products/Combination Treatment Modalities | 21 | 1 |
| Pipeline Products Out-Licensed Products | 22 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 23 | 1 |
| Eisai Co., Ltd. Pipeline Products Glance | 24 | 9 |
| Eisai Co., Ltd. Late Stage Pipeline Products | 24 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 24 | 1 |
| Filing rejected/Withdrawn Products/Combination Treatment Modalities | 25 | 1 |
| Phase III Products/Combination Treatment Modalities | 26 | 1 |
| Eisai Co., Ltd. Clinical Stage Pipeline Products | 27 | 1 |
| Phase II Products/Combination Treatment Modalities | 27 | 1 |
| Phase I Products/Combination Treatment Modalities | 28 | 2 |
| Eisai Co., Ltd. Early Stage Pipeline Products | 30 | 1 |
| Preclinical Products/Combination Treatment Modalities | 30 | 2 |
| Discovery Products/Combination Treatment Modalities | 32 | 1 |
| Eisai Co., Ltd. Drug Profiles | 33 | 83 |
| donepezil hydrochloride | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| eribulin mesylate | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 6 |
| lenvatinib mesylate | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 7 |
| lorcaserin hydrochloride | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 4 |
| mitiglinide | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 2 |
| perampanel | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 3 |
| clevudine | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 2 |
| mecobalamin | 58 | 1 |
| Product Description | 58 | 1 |
| Mechanism of Action | 58 | 1 |
| R&D Progress | 58 | 1 |
| avatrombopag | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 2 |
| fosravuconazole | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 2 |
| lemborexant | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 2 |
| BAN-2401 | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 2 |
| denileukin diftitox | 67 | 1 |
| Product Description | 67 | 1 |
| Mechanism of Action | 67 | 1 |
| R&D Progress | 67 | 3 |
| E-2609 | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| E-3710 | 71 | 1 |
| Product Description | 71 | 1 |
| Mechanism of Action | 71 | 1 |
| R&D Progress | 71 | 2 |
| E-7820 | 73 | 1 |
| Product Description | 73 | 1 |
| Mechanism of Action | 73 | 1 |
| R&D Progress | 73 | 1 |
| indisulam | 74 | 1 |
| Product Description | 74 | 1 |
| Mechanism of Action | 74 | 1 |
| R&D Progress | 74 | 2 |
| Vaccine for Metastatic Melanoma | 76 | 1 |
| Product Description | 76 | 1 |
| Mechanism of Action | 76 | 1 |
| R&D Progress | 76 | 1 |
| E-6011 | 77 | 1 |
| Product Description | 77 | 1 |
| Mechanism of Action | 77 | 1 |
| R&D Progress | 77 | 1 |
| E-6201 | 78 | 1 |
| Product Description | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| R&D Progress | 78 | 2 |
| E-7449 | 80 | 1 |
| Product Description | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| R&D Progress | 80 | 1 |
| golvatinib + lenvatinib | 81 | 1 |
| Product Description | 81 | 1 |
| Mechanism of Action | 81 | 1 |
| R&D Progress | 81 | 2 |
| golvatinib tartrate | 83 | 1 |
| Product Description | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress | 83 | 2 |
| tazemetostat | 85 | 1 |
| Product Description | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| R&D Progress | 85 | 2 |
| donepezil hydrochloride Patch | 87 | 1 |
| Product Description | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| R&D Progress | 87 | 2 |
| E-2027 | 89 | 1 |
| Product Description | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| R&D Progress | 89 | 1 |
| E-7046 | 90 | 1 |
| Product Description | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| R&D Progress | 90 | 1 |
| E-7090 | 91 | 1 |
| Product Description | 91 | 1 |
| Mechanism of Action | 91 | 1 |
| R&D Progress | 91 | 1 |
| E-7389LF | 92 | 1 |
| Product Description | 92 | 1 |
| Mechanism of Action | 92 | 1 |
| R&D Progress | 92 | 1 |
| SJ-733 | 93 | 1 |
| Product Description | 93 | 1 |
| Mechanism of Action | 93 | 1 |
| R&D Progress | 93 | 1 |
| AT-791 | 94 | 1 |
| Product Description | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| R&D Progress | 94 | 1 |
| E-2072 | 95 | 1 |
| Product Description | 95 | 1 |
| Mechanism of Action | 95 | 1 |
| R&D Progress | 95 | 1 |
| E-2508 | 96 | 1 |
| Product Description | 96 | 1 |
| Mechanism of Action | 96 | 1 |
| R&D Progress | 96 | 1 |
| E-5539 | 97 | 1 |
| Product Description | 97 | 1 |
| Mechanism of Action | 97 | 1 |
| R&D Progress | 97 | 1 |
| E-6446 | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| R&D Progress | 98 | 1 |
| ER-358063 | 99 | 1 |
| Product Description | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| R&D Progress | 99 | 1 |
| ER-410660 | 100 | 1 |
| Product Description | 100 | 1 |
| Mechanism of Action | 100 | 1 |
| R&D Progress | 100 | 1 |
| ER-886046 | 101 | 1 |
| Product Description | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| R&D Progress | 101 | 1 |
| ER-901356 | 102 | 1 |
| Product Description | 102 | 1 |
| Mechanism of Action | 102 | 1 |
| R&D Progress | 102 | 1 |
| Small Molecule for Epilepsy | 103 | 1 |
| Product Description | 103 | 1 |
| Mechanism of Action | 103 | 1 |
| R&D Progress | 103 | 1 |
| Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders | 104 | 1 |
| Product Description | 104 | 1 |
| Mechanism of Action | 104 | 1 |
| R&D Progress | 104 | 1 |
| Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders | 105 | 1 |
| Product Description | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| R&D Progress | 105 | 1 |
| Small Molecule to Inhibit Cytidine Deaminase for Oncology | 106 | 1 |
| Product Description | 106 | 1 |
| Mechanism of Action | 106 | 1 |
| R&D Progress | 106 | 1 |
| Small Molecule to Inhibit GWT1 Protein for Malaria | 107 | 1 |
| Product Description | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| R&D Progress | 107 | 1 |
| E-209 | 108 | 1 |
| Product Description | 108 | 1 |
| Mechanism of Action | 108 | 1 |
| R&D Progress | 108 | 1 |
| Small Molecules for Bacterial Infections | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 109 | 1 |
| R&D Progress | 109 | 1 |
| Small Molecules for Chagas Disease | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| R&D Progress | 110 | 1 |
| Small Molecules for Lymphatic Filariasis and Onchocerciasis | 111 | 1 |
| Product Description | 111 | 1 |
| Mechanism of Action | 111 | 1 |
| R&D Progress | 111 | 1 |
| Small Molecules for Malaria | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 1 |
| Small Molecules for Oncology | 113 | 1 |
| Product Description | 113 | 1 |
| Mechanism of Action | 113 | 1 |
| R&D Progress | 113 | 1 |
| Small Molecules for Tuberculosis | 114 | 1 |
| Product Description | 114 | 1 |
| Mechanism of Action | 114 | 1 |
| R&D Progress | 114 | 1 |
| TRI-4 | 115 | 1 |
| Product Description | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| R&D Progress | 115 | 1 |
| Eisai Co., Ltd. Pipeline Analysis | 116 | 16 |
| Eisai Co., Ltd. Pipeline Products by Target | 116 | 7 |
| Eisai Co., Ltd. Pipeline Products by Route of Administration | 123 | 1 |
| Eisai Co., Ltd. Pipeline Products by Molecule Type | 124 | 1 |
| Eisai Co., Ltd. Pipeline Products by Mechanism of Action | 125 | 7 |
| Eisai Co., Ltd. Recent Pipeline Updates | 132 | 36 |
| Eisai Co., Ltd. Dormant Projects | 168 | 2 |
| Eisai Co., Ltd. Discontinued Pipeline Products | 170 | 5 |
| Discontinued Pipeline Product Profiles | 170 | 1 |
| APX-3330 | 170 | 1 |
| atopaxar | 171 | 1 |
| decitabine | 171 | 1 |
| denileukin diftitox | 171 | 1 |